AI, machine learning offer hope for speeding Alzheimer's development

"Unlearn.AI Inc., of San Francisco, has developed a process to create digital twins of Alzheimer's disease patients in the active-treatment group that predict how they would perform if they weren't given drug. The company's Digenesis process uses historical clinical trial datasets from patients who participated in the control arms of clinical trials to create the twins who are a mash-up of multiple patients in the studies."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.